
IN8bio (INAB) announced updated clinical data from its INB-200 and INB-400 programs in newly diagnosed glioblastoma, presented in an oral session at the 2026 Society for Neuro-Oncology annual meeting in
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| INAB | IN8bio | 0.78 | -0.84 | -51.85% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.78 | -51.85% |

IN8bio (INAB) announced updated clinical data from its INB-200 and INB-400 programs in newly diagnosed glioblastoma, presented in an oral session at the 2026 Society for Neuro-Oncology annual meeting in

In8bio, Inc. (INAB) has disclosed a new risk, in the Brand / Reputation category. In8bio, Inc. faces growing exposure to reputational and regulatory risks as information about its programs and

IN8bio, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Boris Peaker from JonesTrading maintained a Buy rating on the stock and has a $5.00 price

“This quarter we continued to build upon our deep expertise in gammadelta T cells, officially welcoming Dr. Polyakova to the team and making progress with our proprietary TCE platform,” said

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on IN8bio. The associated price target remains the same with $6.00. Swayampakula Ramakanth has given his Buy rating due

“The second quarter marked an important period of scientific and clinical validation for gammadelta T cell therapeutics and IN8bio (INAB). Our gammadelta TCE platform is progressing, with INB-619 advancing into

IN8bio (INAB) announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in The Journal of Clinical Oncology. “These peer-reviewed results validate the scientific foundation of

IN8bio (INAB) announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 studies at the 2026 American Society of Clinical Oncology, or ASCO, annual meeting. Among patients

IN8bio ( ($INAB) ) has provided an update. On June 1, 2026, IN8bio, Inc. entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC to establish an

An update from IN8bio ( ($INAB) ) is now available. IN8bio, Inc., a clinical-stage biopharmaceutical company developing γδ T cell therapies and γδ T cell engagers for cancer and autoimmune
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 18, 2027TBA | $8.86M | $-0.21 | $0.00 | 0.01 | -0.69 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.